BACKGROUND: Little data are available about the hospital management of patients with decompensated heart failure (HF) with individual and combination medical therapies, particularly from the more generalizable perspective of a population-based investigation. The purpose of our study was to describe the use of different cardiac medications in 2463 patients with new-onset HF who were discharged from all greater Worcester, Massachusetts, hospitals during 2000. METHODS: On the basis of a review of medical records, we examined the prescribing of 2 classes of cardiac medications that have been shown to improve the long-term prognosis of patients with HF (angiotensin pathway inhibitors and beta-blockers). We also examined the use of 2 therapies commonly used to improve the symptomatic status of patients with acute HF (diuretics and digoxin). RESULTS: The mean age of the study sample was 76 years, and 57% were women. Approximately 1 in 5 patients were not prescribed beta-blockers or angiotensin inhibitors during their index hospitalization, whereas 1 in 3 patients were discharged with both of these effective cardiac medications. Diuretics were prescribed for virtually all patients (98%), followed by the use of digoxin in approximately half of patients (48%). The receipt of both beta-blockers and angiotensin pathway inhibitors was associated with several demographic, medical history, and clinical factors. Patients treated with both effective cardiac medications were also more likely to be counseled to monitor or modify several lifestyle factors that have been shown to be effective adjuncts to the medical management of patients with HF. CONCLUSIONS: Considerable opportunity remains for the more optimal hospital management of patients with decompensated HF.
BACKGROUND: Little data are available about the hospital management of patients with decompensated heart failure (HF) with individual and combination medical therapies, particularly from the more generalizable perspective of a population-based investigation. The purpose of our study was to describe the use of different cardiac medications in 2463 patients with new-onset HF who were discharged from all greater Worcester, Massachusetts, hospitals during 2000. METHODS: On the basis of a review of medical records, we examined the prescribing of 2 classes of cardiac medications that have been shown to improve the long-term prognosis of patients with HF (angiotensin pathway inhibitors and beta-blockers). We also examined the use of 2 therapies commonly used to improve the symptomatic status of patients with acute HF (diuretics and digoxin). RESULTS: The mean age of the study sample was 76 years, and 57% were women. Approximately 1 in 5 patients were not prescribed beta-blockers or angiotensin inhibitors during their index hospitalization, whereas 1 in 3 patients were discharged with both of these effective cardiac medications. Diuretics were prescribed for virtually all patients (98%), followed by the use of digoxin in approximately half of patients (48%). The receipt of both beta-blockers and angiotensin pathway inhibitors was associated with several demographic, medical history, and clinical factors. Patients treated with both effective cardiac medications were also more likely to be counseled to monitor or modify several lifestyle factors that have been shown to be effective adjuncts to the medical management of patients with HF. CONCLUSIONS: Considerable opportunity remains for the more optimal hospital management of patients with decompensated HF.
Authors: Timothy P Fitzgibbons; Olga T Hardy; Darleen Lessard; Joel M Gore; Jorge Yarzebski; Robert J Goldberg Journal: Coron Artery Dis Date: 2009-12 Impact factor: 1.439
Authors: Molly E Waring; Jane S Saczynski; David McManus; Michael Zacharias; Darleen Lessard; Joel M Gore; Robert J Goldberg Journal: Am J Med Date: 2011-09 Impact factor: 4.965
Authors: Robert J Goldberg; Frederick A Spencer; Mariana Szklo-Coxe; Mayra Tisminetzky; Jorge Yarzebski; Darleen Lessard; Joel M Gore; William Gaasch Journal: Clin Cardiol Date: 2010-06 Impact factor: 2.882
Authors: Andrew H Coles; Kimberly Fisher; Chad Darling; Jorge Yarzebski; David D McManus; Joel M Gore; Darleen Lessard; Robert J Goldberg Journal: Am J Cardiol Date: 2014-07-02 Impact factor: 2.778
Authors: Jane S Saczynski; Chad E Darling; Frederick A Spencer; Darleen Lessard; Joel M Gore; Robert J Goldberg Journal: J Am Geriatr Soc Date: 2009-08-13 Impact factor: 5.562
Authors: Robert J Goldberg; Jordan H Goldberg; Sean Pruell; Jorge Yarzebski; Darleen Lessard; Frederick A Spencer; Joel M Gore Journal: Am J Med Date: 2008-03 Impact factor: 4.965
Authors: David Park; David McManus; Chad Darling; Jordan H Goldberg; Joel M Gore; Darleen Lessard; Robert J Goldberg Journal: Clin Epidemiol Date: 2011-11-22 Impact factor: 4.790
Authors: Samuel W Joffe; Kristy Webster; David D McManus; Michael S Kiernan; Darleen Lessard; Jorge Yarzebski; Chad Darling; Joel M Gore; Robert J Goldberg Journal: J Am Heart Assoc Date: 2013-05-15 Impact factor: 5.501